FDA granted accelerated approval to Novartis AG’s HDAC inhibitor Farydak (panobinostat) for third-line treatment of multiple myeloma even though the drug’s Phase III confirmatory trial will not begin for approximately three years.
The agency’s approval letter includes two post-marketing trial requirements as a condition for accelerated approval: a Phase II...